Compositions for inhibiting atherosclerosis

Details Compositions for inhibiting atherosclerosis Compositions for inhibiting atherosclerosis

2008-02-19

2010-06-08

Monshipouri, Maryam (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C435S006120

Reexamination Certificate

active

07732410

ABSTRACT:
The present invention relates to compositions and methods for the reduction of atherosclerotic plaques and the decrease in the level of total serum cholesterol, triglycerides, serum LDL cholesterol, and serum HDL cholesterol.

REFERENCES:
patent: 5596091 (1997-01-01), Switzer
patent: 6281199 (2001-08-01), Gupta
patent: 7108851 (2006-09-01), Higuchi et al.
patent: 7335638 (2008-02-01), Higuchi
patent: 2003/0124109 (2003-07-01), Higuchi et al.
patent: 2005/0142116 (2005-06-01), Higuchi
patent: 2009/0068167 (2009-03-01), Higuchi
patent: WO/02/02050 (2002-01-01), None
patent: WO/03/082324 (2003-10-01), None
patent: WO/2006/034560 (2006-04-01), None
Mar. 21, 2006 Notice of Allowance in U.S. Appl. No. 10/086,913.
Nov. 9, 2005 Response to Final Office Action in U.S. Appl. No. 10/086,913.
Oct. 24, 2005 Notice of Allowance in U.S. Appl. No. 10/086,913.
Jul. 29, 2005 Response to Non-Final Office Action in U.S. Appl. No. 10/086,913.
Jan. 27, 2005 Non-Final Office Action in U.S. Appl. No. 10/086,913.
Oct. 1, 2007 Notice of Allowance in U.S. Appl. No. 10/952,003.
Sep. 7, 2007 Request for Continued Examination in U.S. Appl. No. 10/952,003.
Jul. 30, 2007 Notice of Allowance in U.S. Appl. No. 10/952,003.
Apr. 23, 2007 Response to Non-Final Office Action in U.S. Appl. No. 10/952,003.
Jan. 23, 2007 Non-Final Office Action in U.S. Appl. No. 10/952,003.
Agusti, et al., 1997, “The trans-sialidase ofTrypanosome cruziis anchored by two different lipids,” Glycobiology, vol. 7, No. 6: p. 731-735.
Aiello, et al., 2002, “A possible role for complement in the pathogenesis of chronic chagasic cardiomyopathy,” Journal of Pathology, vol. 197: p. 224-229.
Akira et al., “Toll-like receptors: critical proteins linking innate and acquired immunity,” Nature Immunol. 2:675-680(2001).
Amaya, et al., 2004, “Structural Insights into the catalytic mechanism ofTrypanosoma cruzitrans-sialidase,” Structure, vol. 12: p. 775-784.
Amend et al., “Energetics of overall metabolic reactions of thermophilic and hyperthermophilic archaea and bacteria,” F.E.M.S. Microbiol. Rev. 25: 175-243 (2001).
Baseman, et al., 1982, “Sialic acid residues mediateMycoplasma pneumoniaeattachment to human and sheep erythrocytes,” Infect. Immun., vol. 38, No. 1: p. 389-391.
Berbec, et al., 1999, “Total serum sialic acid concentration as a supporting marker of malignancy in ovarian neoplasia,” Eur. J. Gynaecol on Col., vol. 20, No. 5-6: p. 389-392.
Blanchard, et al., 1994, “AIDS-associated mycoplasmas,” Annu. Rev. Microbiol., vol. 48: p. 687-712.
Bredt, et al., 1982, “Adherence of mycoplasmas: phenomena and possible role in the pathogenesis of disease,” Infection, vol. 10, No. 3: p. 199-201.
Briones, et al., 1993, “Trypanosoma cruzitrans-sialidase homologue,” Accession No. AAC98544, GI:624626, 736 aa.
Buscaglia, et al., 1998, “The repetitive domain ofTrypanosome cruzitrans-sialidase enhances the immune response against the catalytic domain,” J. Infect. Dis., vol. 177, No. 2: p. 431-436.
Buscaglia, et al., 1999, “Tandem amino acid repeats fromTrypanosoma cruzished antigens increase the half-life of proteins in blood,” Blood, vol. 93: p. 2025-2032.
Buschiazzo, et al., 1996, “Medium scale production and purification to homogeneity of a recombinant trans-sialidase fromTrypanosoma cruzi,” Cell Mol. Biol., vol. 42: p. 703-710.
Buschiazzo, et al., 2002, “The Crystal Structure and Mode of Action of Trans-sialidase, a key enzyme inTrypanosoma cruzipathogenesis,” Molecular Cell, vol. 10: p. 757-758.
Campetella, et al., 1994, “A recombinantTrypanosoma cruzitrans-sialidase lacking the amino acid repeats retains the enzymatic activity,” Mol. Biochem. Parasitol., vol. 64: p. 337-340.
Chandler, et al., 1982, “Mycoplasma pneumoniaeattachment: competitive inhibition by mycoplasmal binding component and by sialic acid-containing glycoconjugates,” Infect. Immun., vol. 38, No. 2: p. 598-603.
Chen et al., “Apoptosis of hepatoma cells SMMC-7721 induced byGinkgo bilobaseed polysaccharide,” World J. Gastroenterol. 8: 832-6 (2002).
Chen et al., 1986, “Carditis associated withMycoplasma pneumoniaeinfection,” Am. J. Dis. Child., vol. 140: p. 471-472.
Clyde et al., “Tropism forMycoplasma gallisepticumfor arterial walls,” Proc. Natl. Acad. Sci. U.S.A. 70: 1545-1549 (1973).
Cole, 1997 “Mycoplasma interactions with the immune system: implications for disease pathology,” http://www.compkarori.com/arthritis/pil6002.htm.
Cole, 1999, “Mycoplasma-induced arthritis in animals: relevance to understanding the etiologies of the human rheumatic diseases,” Rev. Rhum. Engl. Ed. 66, 1Suppl: p. 45S-49S.
Collier and Clyde, “Relationships betweenM. pneumoniaeand human respiratory epithelium,” Infect. Immun. 3:694-701 (1971).
Cremona, et al., 1995, “A single tyrosine differentiates active and inactiveTrypanosome cruzitrans-sialidase,” Gene, vol. 160: p. 123-128.
Cremona, et al., 1996, “Effect of primary structure modifications inTrypanosoma cruzineuramindase trans-sialidase activities,” Cell. Mol. Biol., vol. 42: p. 697-702.
Dallo, et al., 2000, “Intracellular DNA replication and long term survival of pathogenic mycoplasmas” Microbial Pathogenesis vol. 29: p.301-309.
Damy et al,. “Coinfection of laboratory rats withMycoplasma pulmonisandChlamydia pneumoniae,” Contemp. Top.Am.Assoc.Lab.An.Sci. 42: 52-56 (2003).
Danesch, et al., 1997, “Chronic infections and coronary artery disease: is there a link?” Lancet, vol. 350: p. 430-436.
Fagundes RQ. Study of co-participation of natural infection byChlamydophila pneumoniaeandMycoplasma pneumoniaein experimental atherogenesis in rabbits. Doctoral thesis presented at the Heart Institute of Clinical Hospitial, in the Cardiology Sciences Post Graduation Program of São Paulo University School of Medicine, Mar. 17, 2006. (The Summary is in the English language).
Farraji, et al., 1997, “Mycoplasma-associated pericarditis,” Mayo Clin. Proc., vol. 72: p. 33-36.
Fearon et al., “Cancer cachexia,” Int. J. Cardiol 85: 73-81 (2002).
Feng Shaw-Huey, et al., 1999, “Mycoplasma infections prevent apoptosis and induce malignant transformation of interleukin-3-dependent 32D hematopoietic cells,” Mol. Cel. Biol., vol. 19, No. 12: p. 7995-8002.
Florin THJ et al., “Shared and unique environmental factors determine the ecology of methanogens in humans and rats,” Am. J. Gastroenterol. 95: 2872-2879 (2000).
Fu et al., 1998, “Middle cerebral artery occlusion after recentMycoplasma pneumoniaeinfection,” J. Neurol. Sci., vol. 157: p. 113-115.
Gabridge and Taylor-Robinson, “Interaction ofMycoplasma pneumoniaewith human lung fibroblasts: role of receptor sites,” Infect. Immun. 25:455-459 (1979).
Giles et al., “Androgenetic alopecia and prostate cancer: findings from an Australian case-control study,” Cancer Epidemiol. Biomarkers Prev 11: 549-553 (2002).
Glasgow and Hill, “Interactions ofMycoplasma gallisepticumwith sialyl glycoproteins,” Infect. Immun. 30:353-361 (1980).
Gurfinkel, et al., 1997, “IgG antibodies to chlamydial and mycoplasma infection plus C-reactive protein related to poor outcome in unstable angina,” Arch. Inst. Cardiol. Mex., vol. 67: p. 462-468.
Hansen, et al., 1981, “Characterization of hemadsorption-negative mutants ofMycoplasma pneumoniae,” Infect. Immun., vol. 32: p. 127-136.
Higuchi et al., “Mycoplasma pneumoniaeandChlamydia pneumoniaein calcified nodules of aortic stenotic valves,” Rev Inst Med trop S.Paulo 44:209-212 (2002).
Higuchi et al., 2000, “Detection ofMycoplasma pneumoniaeandChlamydia pneumoniaein ruptured atherosclerotic plaques,” Braz. J. Med. Biol. Res. 33:1023-1026.
Higuchi et al., 2006, “Co-infection

Affiliated with

Also associated with

Rating

Compositions for inhibiting atherosclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions for inhibiting atherosclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for inhibiting atherosclerosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4166225